Skip to main content
icon for Eli Lilly licenses Peptron’s SmartDepot by October 7?
Технологии·Eli Lilly

Eli Lilly licenses Peptron’s SmartDepot by October 7?

icon for Eli Lilly licenses Peptron’s SmartDepot by October 7?
Технологии·Eli Lilly

Eli Lilly licenses Peptron’s SmartDepot by October 7?

13% вероятность
Polymarket

$11,264 Объем

13% вероятность
Polymarket

$11,264 Объем

This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly has conducted only initial non-commercial research under its 2024 evaluation agreement with Peptron on the SmartDepot sustained-release microsphere platform, with no verified commercial licensing, technology transfer, or binding deal announced as of mid-August 2026. Recent reporting highlights Lilly's pivot toward alternatives like Camurus for long-acting peptide formulations and ongoing doubts about SmartDepot validation timelines, fueling trader skepticism. With the October 7 resolution date approaching, the absence of concrete milestones or executive statements sustains the 87.5% implied probability on No, though an unexpected announcement in the next eight weeks remains the key swing factor.

This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.

Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.

Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.

The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Объем
$11,264
Дата окончания
7 окт. 2026 г.
Открытие рынка
May 5, 2026, 8:02 PM ET

Resolver

0x65070BE91...
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly has conducted only initial non-commercial research under its 2024 evaluation agreement with Peptron on the SmartDepot sustained-release microsphere platform, with no verified commercial licensing, technology transfer, or binding deal announced as of mid-August 2026. Recent reporting highlights Lilly's pivot toward alternatives like Camurus for long-acting peptide formulations and ongoing doubts about SmartDepot validation timelines, fueling trader skepticism. With the October 7 resolution date approaching, the absence of concrete milestones or executive statements sustains the 87.5% implied probability on No, though an unexpected announcement in the next eight weeks remains the key swing factor.

This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.

Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.

Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.

The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Объем
$11,264
Дата окончания
7 окт. 2026 г.
Открытие рынка
May 5, 2026, 8:02 PM ET

Resolver

0x65070BE91...
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.

Связанные

icon for Одобрит ли FDA Ретатрутид в этом году?

Одобрит ли FDA Ретатрутид в этом году?

3%
Да
icon for Отключение ChatGPT к 31 августа 2026 года?

Отключение ChatGPT к 31 августа 2026 года?

76%
Да
icon for SSI объявляет, что достиг SSI к 31 декабря?

SSI объявляет, что достиг SSI к 31 декабря?

11%
Да

Не доверяй внешним ссылкам.

Часто задаваемые вопросы

«Eli Lilly licenses Peptron’s SmartDepot by October 7?» — это рынок прогнозов на Polymarket, где трейдеры покупают и продают акции «Да» или «Нет» в зависимости от того, верят ли они, что это событие произойдёт. Текущая вероятность по мнению сообщества составляет 13% для «Yes». Например, если «Да» торгуется по 13¢, рынок коллективно оценивает вероятность наступления события в 13%. Эти коэффициенты постоянно меняются по мере реакции трейдеров на новые события и информацию. Акции правильного исхода можно обменять на $1 каждую при разрешении рынка.

На сегодняшний день «Eli Lilly licenses Peptron’s SmartDepot by October 7?» сгенерировал общий объём торгов $11.3K с момента запуска рынка May 5, 2026. Такой уровень активности отражает высокую вовлечённость сообщества Polymarket и гарантирует, что текущие коэффициенты формируются широким кругом участников рынка. Ты можешь отслеживать движение цен в реальном времени и торговать любым исходом прямо на этой странице.

Чтобы торговать на «Eli Lilly licenses Peptron’s SmartDepot by October 7?», просто выбери, считаешь ли ты, что ответ — «Да» или «Нет». Каждая сторона имеет текущую цену, отражающую подразумеваемую вероятность рынка. Введи сумму и нажми «Торговать». Если ты купишь акции «Да» и исход разрешится как «Да», каждая акция принесёт $1. Если исход — «Нет», твои акции «Да» принесут $0. Ты также можешь продать свои акции в любой момент до разрешения, чтобы зафиксировать прибыль или ограничить убыток.

Текущая вероятность для «Eli Lilly licenses Peptron’s SmartDepot by October 7?» составляет 13% для «Yes». Это означает, что сообщество Polymarket в настоящее время оценивает вероятность наступления этого события в 13%. Эти коэффициенты обновляются в реальном времени на основе реальных сделок, предоставляя постоянно обновляемый сигнал ожиданий рынка.

Правила разрешения «Eli Lilly licenses Peptron’s SmartDepot by October 7?» точно определяют, что должно произойти, чтобы каждый исход был объявлен победителем, включая официальные источники данных, используемые для определения результата. Ты можешь просмотреть полные критерии разрешения в разделе «Правила» на этой странице над комментариями. Мы рекомендуем внимательно прочитать правила перед торговлей, так как они определяют точные условия, особые случаи и источники.